New TrialNet research findings published today in Science Translational Medicine show that a 14-day course of the immunotherapy drug teplizumab provided an additional year of delay in onset of type 1 diabetes and improved insulin production, increasing the overall benefit to high-risk individuals reported in the original study fin
Teplizumab Prevention Study Chair Kevan Herold, M.D., Yale University, presented first-of-a-kind findings showing that teplizumab delayed type 1 diabetes a median of 2 years in children and adults at high risk. Findings were also simultaneously published in the New England Journal of Medicine
Study Confirms Positive Lasting Effects of Low-dose Thymoglobulin® in Newly Diagnosed Type 1 Diabetes
Findings from a TrialNet clinical study published in Diabetes show low-dose Thymoglobulin® preserved insulin production and improved long-term blood sugar control for 2 years in people newly diagnosed with type 1 diabetes.